VIDEO: Erythropoiesis-stimulating therapy-resistance presents challenge for dialysis patients

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I think the biggest challenges in the dialysis population is ESA resistance. These are patients who need, either very high doses of ESA or despite high doses, just don't get to what we would consider an adequate hemoglobin, which is generally, about 10 or above. In these patients, Vadadustat may offer a second route to attempt to manage these patients, and some of them undoubtedly, will do well with it. It's not clear yet whether these drugs are superior in these ESA resistant patients, but certainly, it represents another option that we prior to this, didn't have. In the non-dialysis population, there is underutilization of both oral and IV iron that compromises higher hemoglobins in this population, and if we can get physicians to be more ready to use those agents, we'll see less anemia, and probably patients feeling better, because iron deficiency can cause fatigue.